Eli Lilly seeks emergency use authorization for effective antibody treatment

Eli Lilly research facility.
(Image credit: jetcityimage/iStock)

Eli Lilly has determined its monoclonal antibody treatment reduces patients' COVID-19 viral load and helps them avoid hospitalization, it announced Wednesday.

The treatment involves combining two antibodies and injecting them into patients — similar to the treatment developed by Regeneron that President Trump received. Less than 1 percent of patients sick with COVID-19 and injected with the treatment went to the hospital, compared to 5.8 percent who had a placebo, Eli Lilly's study found. And at the end of 11 days, the antibody combination "significantly reduced" the amount of virus found in patients' nasal swabs.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Kathryn Krawczyk

Kathryn is a graduate of Syracuse University, with degrees in magazine journalism and information technology, along with hours to earn another degree after working at SU's independent paper The Daily Orange. She's currently recovering from a horse addiction while living in New York City, and likes to share her extremely dry sense of humor on Twitter.